Biotech
Arcellx
Arcellx raises $125M Series C at $1.5B valuation
$125M
Total Raised
Series C
Latest Round
2014
Founded
200+
Employees
9000 Virginia Manor Road, Beltsville, MD 20705
1 min read
Quick Facts
Valuation
$1.5B
Latest Round Size
$125M
Latest Round Date
June 2024
Arcellx: Series C Funding Round
Arcellx has successfully raised $125M in Series C funding, reaching a valuation of $1.5B.
Company Overview
Cell therapy company
Funding Details
The Series C round was led by Betta Pharmaceuticals, with participation from Ally Bridge Group, Frazier Healthcare Partners, EcoR1 Capital.
Company Information
- Headquarters: 9000 Virginia Manor Road, Beltsville, MD 20705
- Founded: 2014
- Employees: 200+
- Category: Biotech
Investment
Arcellx plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Betta Pharmaceuticals: Verified investor in Series C
- Ally Bridge Group: Verified investor in Series C
- Frazier Healthcare Partners: Verified investor in Series C
- EcoR1 Capital: Verified investor in Series C
Key Investors
Betta Pharmaceuticals
Lead Investor
Verified investor in Series C
Ally Bridge Group
Investor
Verified investor in Series C
Frazier Healthcare Partners
Investor
Verified investor in Series C
EcoR1 Capital
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M